ABSSSI
Showing 1 - 25 of 48
Diabetes, Wound Infection, ABSSSI Trial in Hartford (Tebipenem Pivoxil Hydrobromide)
Enrolling by invitation
- Diabetes
- +3 more
- Tebipenem Pivoxil Hydrobromide
-
Hartford, ConnecticutHartford Hospital
Mar 4, 2022
Dalbavancin and Other Standard of Care of Same Class in ABSSSI
Completed
- Acute Bacterial Skin and Skin Structure Infection
- Xydalba
- vancomycin, teicoplanin or daptomycin
-
Alexandroupolis, Greece
- +15 more
Mar 3, 2022
Acute Bacterial Skin and Skin Structure Infection Trial in United States (Current Formulation of Oritavancin, Kimyrsa)
Completed
- Acute Bacterial Skin and Skin Structure Infection
- Current Formulation of Oritavancin
- Kimyrsa
-
Chula Vista, California
- +3 more
Mar 18, 2021
Bacterial Infections, Infection Trial in United States (BC-3781, Vancomycin)
Completed
- Bacterial Infections
- Infection
-
Chula Vista, California
- +8 more
Oct 29, 2020
Sivextro in Acute Bacterial Skin and Skin Structure Infection in
Terminated
- Skin Disease, Infectious
- Tedizolid (Sivextro, BAY1192631)
- Linezolid
-
Multiple Locations, Mexico
- +2 more
Sep 30, 2019
Acute Bacterial Skin and Skin Structure Infections Trial in India (Oral Levonadifloxacin/Linezolid Tablet, Intravenous
Completed
- Acute Bacterial Skin and Skin Structure Infections
- Oral Levonadifloxacin/Linezolid Tablet
- Intravenous Levonadifloxacin/Linezolid Infusion
-
Hyderabad, Andhra Pradesh, India
- +31 more
Jun 26, 2020
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection Trial in New York (Dalbavancin, Usual Care)
Completed
- Bacterial Infections
- Acute Bacterial Skin and Skin Structure Infection
- Dalbavancin
- Usual Care
-
New York, New YorkWeill Cornell Medicine
Jan 7, 2020
Acute Bacterial Skin and Skin Structure Infections Trial in United States (Usual Care, Dalbavancin)
Completed
- Acute Bacterial Skin and Skin Structure Infections
- Usual Care
- Dalbavancin
-
Phoenix, Arizona
- +10 more
Mar 27, 2020
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections Trial in Worldwide
Recruiting
- Methicillin-Resistant Staphylococcus Aureus
- +2 more
- Dalbavancin single dose
- +2 more
-
Mobile, Alabama
- +26 more
Jan 27, 2023
Acute Bacterial Skin and Skin Structure Infections Trial in Worldwide (ceftobiprole medocaril, vancomycin+aztreonam)
Completed
- Acute Bacterial Skin and Skin Structure Infections
- ceftobiprole medocaril
- vancomycin+aztreonam
-
Anaheim, California
- +33 more
Mar 7, 2022
Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections Trial in San Diego (TNP-2092, Vancomycin)
Completed
- Skin and Subcutaneous Tissue Bacterial Infections
- Gram-Positive Bacterial Infections
-
San Diego, CaliforniaeStudy Site
Oct 10, 2020
Bacterial Infections Trial in United States (Debio 1450 IV, Debio 1450 Oral, Linezolid)
Completed
- Bacterial Infections
- Debio 1450 IV
- +5 more
-
Anaheim, California
- +21 more
Oct 24, 2019
Wound Infection, Abscess, Systemic Inflammation Trial in La Mesa (Single-Dose IV Oritavancin Diphosphate, IV Vancomycin)
Completed
- Wound Infection
- +3 more
- Single-Dose IV Oritavancin Diphosphate
- IV Vancomycin
-
La Mesa, CaliforniaSharp Grossmont Hospital
Apr 12, 2021
Skin Infection Trial in Shanghai (9MW1411 injection 1 combined with Linezolid, 9MW1411 injection 2 combined with Linezolid,
Recruiting
- Skin Infection
- 9MW1411 injection 1 combined with Linezolid
- +2 more
-
Shanghai, Shanghai, ChinaHuashan Hospital affiliated to Fudan University
Apr 15, 2022
Bacterial Infections, Skin Structures and Soft Tissue Infections Trial in Worldwide (Omadacycline, Linezolid)
Completed
- Bacterial Infections
- Skin Structures and Soft Tissue Infections
-
Mobile, Alabama
- +77 more
Mar 20, 2019
Skin Diseases, Bacterial, Gram-Positive Bacterial Infections Trial in United States (contezolid acefosamil, linezolid 600 mg)
Completed
- Skin Diseases, Bacterial
- Gram-Positive Bacterial Infections
- contezolid acefosamil
- linezolid 600 mg
-
Chula Vista, California
- +6 more
Apr 6, 2021
Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Non-healing Wound Trial (Ultrasonic Drug Delivery, Standard of Care
Unknown status
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Non-healing Wound
- Ultrasonic Drug Delivery
- Standard of Care Antibiotic Treatment
- (no location specified)
Nov 4, 2018
Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders Trial in Aurora (Dalbavancin)
Enrolling by invitation
- Gram-Positive Bacterial Infections
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
May 4, 2021
Skin and Subcutaneous Tissue Bacterial Infections Trial in United States (Delafloxacin, Linezolid, Vancomycin)
Completed
- Skin and Subcutaneous Tissue Bacterial Infections
- Delafloxacin
- +2 more
-
Mobile, Alabama
- +30 more
Sep 25, 2019
Skin Infection, Bacterial Infection Trial in United States (Daptomycin, Brilacidin)
Completed
- Skin Infection
- Bacterial Infection
-
Chula Vista, California
- +3 more
Sep 24, 2018
Bacterial Infections, Skin Structures and Soft Tissue Infections Trial in United States (Omadacycline, Linezolid)
Completed
- Bacterial Infections
- Skin Structures and Soft Tissue Infections
-
Birmingham, Alabama
- +49 more
Nov 28, 2018